Interim guidance while abacavir/lamivudine, abacavir singles, lamivudine singles and abacavir/zidovudine (2nd Line) are out of stock updated 18.07.2019

For patients on an ABC regimen:

- While both 3TC and ABC are out of stock, move patients on an ABC-containing regimen to a Combivir-containing regimen temporarily, 1-4 weeks. Even for those patients with contraindications to AZT, since any drug-induced anaemia or mitochondrial toxicities would be expected to take longer than this to develop. NB this is better than treatment interruption.

- If 3TC comes back in stock sooner than ABC does, an option is to move patients on an ABC-containing regimen to 3TC+d4T instead. Short-term d4T is a great option, but if also short of lamivudine to go with it, then rather use the options above. For patients who had been moved to ABC during an acute kidney injury episode in the distant past, with normal creatinine, try back on a 3TC-Tdf-EFV (or equivalent)-based regimen again. For all patients who are virally supressed, and none of the above alternatives are in stock, move on to typical 1st Line for short period (3TC-Tdf-EFV).

During this ongoing ABC/3TC stockout patients with severe renal disease (CrCl< 30) who cannot access ABC or 3TC, move then onto LPV/r + EFV.

In the near future LPV/r + DTG would also be an option.

But, please keep in mind that you need to increase the dose of LPV/r (3 bid) when combining with EFV instead of 2 bid.

Interim guidance while Darunavir and Dolutegravir singles are out of stock (3rd Line)

- If Darunavir is out of stock, move patients to Lopinavir/Ritonavir
- If Dolutegravir is out of stock, move patients to Raltegravir

Please contact: sahivcs@sahivcs.org if you are unsure about what to do in the absence of these medicines

Please contact Kopano on report@stockouts.org to report any essential medicine stockout